An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases

Trial Profile

An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 24 Sep 2012 Results will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep/Oct 2012.
    • 15 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Actual patients number chnaged from 2 to 24 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top